AQUIPTA Wins EU Approval for Migraine Relief

AbbVie just got the green light from the European Commission for their migraine medication, AQUIPTA, to treat migraines in adults. This means more options for those who suffer from migraines, as the drug has shown to offer relief from pain for up to 48 hours. The approval is based on a Phase 3 ECLIPSE trial that proved AQUIPTA's effectiveness in tackling migraine symptoms. What does it mean for you? If you're in Europe and migraines are your unwanted guest, there's a new sheriff in town to help manage those painful episodes. AQUIPTA could offer you a break from the throbbing headaches and let you reclaim your day.